Boston、MAにおける慢性リンパ性白血病の臨床試験

Bostonとその周辺地域（約30マイル以内）の拠点で、慢性リンパ性白血病に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

被験者募集中第3相

Dana-Farber Cancer Institute, Boston

65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

被験者募集中第3相

Tufts Medical Center, Boston
Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

被験者募集中第3相

Beth Israel Deaconess Medical Center (Bidmc), Boston
Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

被験者募集中第1/2相

Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

被験者募集中第3相

Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/28更新 · NCT07277231

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

被験者募集中第1/2相

Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/28更新 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

被験者募集中第3相

Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

被験者募集中第2相

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/09/11更新 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

被験者募集中第1/2相

Research Site, Boston

18歳以上 · 全性別 · 2026/09/08更新 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

被験者募集中第1相

Tufts Medical Center, Boston

18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

被験者募集中第1/2相

Massachusetts General Hospital, Boston

12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

被験者募集中第4相

Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/08/11更新 · NCT07426484

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

被験者募集中第2相

Massachusetts General Hospital, Boston

18歳以上 · 全性別 · 2026/08/11更新 · NCT06849713

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

被験者募集中第2相

Research Site, Boston

18歳〜130歳 · 全性別 · 2026/08/06更新 · NCT07024706

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

被験者募集中第1相健康なボランティア歓迎

Brigham and Women's Hospital, Boston

18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07020533

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

被験者募集中第2相

Boston Medical Center, Boston

18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

被験者募集中観察研究

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/05/07更新 · NCT02269592

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

被験者募集中第1相

Dana Farber Cancer Institute, Boston

13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

被験者募集中観察研究

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/04/24更新 · NCT00131014

Understanding Chronic Lymphocytic Leukemia

被験者募集中観察研究

Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/04/24更新 · NCT04028531

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

被験者募集中第2相健康なボランティア歓迎

DFCI/BWH Brigham and Women's Hospital, Boston

18歳〜75歳 · 全性別 · 2026/03/10更新 · NCT06059391

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

被験者募集中第4相

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

被験者募集中第4相

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

被験者募集中第1相

Beth Israel Deaconess Medical Center, Boston

18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

被験者募集中第1/2相

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/02/11更新 · NCT06644183

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

被験者募集中第2相

Dana-Farber Cancer Institute /ID# 230061, Boston

18歳以上 · 全性別 · 2026/02/09更新 · NCT04895436

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

被験者募集中第2相

Beth Israel Deaconess Medical Center, Boston
Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/01/21更新 · NCT06333262

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

被験者募集中第2相

Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2026/01/07更新 · NCT06043674

Mosunetuzumab for CLL MRD Clearance

被験者募集中第1/2相

Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2025/12/15更新 · NCT07052695

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

被験者募集中第2相

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2025/12/05更新 · NCT05168930

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

被験者募集中第1相

Dana-Farber Cancer Institute, Boston

18歳以上 · 全性別 · 2025/07/17更新 · NCT04704323

他の都市における慢性リンパ性白血病の試験

Bostonにおける他の研究

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。